论文部分内容阅读
目的观察FOLFOX方案与XELOX运用于Ⅱ/Ⅲ期结肠癌辅助化疗中的疗效及不良反应。方法选择2011年5月至2014年4月接受治疗的Ⅱ/Ⅲ期结肠癌患者92例作为研究对象,随机分为两组,各46例。对照组应用FOLFOX化疗方案;观察组应用XELOX化疗方案。比较两组患者2年无病生存率和总生存率,观察化疗前后两组患者生存质量的变化情况,对比两组患者化疗阶段腹泻、恶心呕吐等不良反应的发生情况。结果两组患者2年无病生存率和总生存率比较差异无统计学意义(P均>0.05);化疗后,两组生存质量评分比较差异无统计学意义(P均>0.05);观察组患者化疗期间不良反应的发生率低于对照组,差异有统计学意义(P<0.05,P<0.01)。结论Ⅱ/Ⅲ期结肠癌患者接受FOLFOX方案与XELOX方案辅助化疗可有效提高患者的生活质量,且两种化疗方案的疗效相近,但XELOX化疗方案的不良反应发生率低,更适用于骨髓储备功能不良、耐受性差的结肠癌患者。
Objective To observe the efficacy and side effects of FOLFOX regimen and XELOX in adjuvant chemotherapy for stage Ⅱ / Ⅲ colon cancer. Methods A total of 92 patients with stage Ⅱ / Ⅲ colon cancer who were treated from May 2011 to April 2014 were selected as study subjects and randomly divided into two groups of 46 patients. The control group was treated with FOLFOX chemotherapy and the observation group with XELOX chemotherapy. Two-year disease-free survival rate and overall survival rate were compared between the two groups. The changes of quality of life before and after chemotherapy were observed. The incidence of diarrhea, nausea and vomiting were compared between the two groups during chemotherapy. Results There was no significant difference in 2-year disease-free survival rate and overall survival between the two groups (P> 0.05). After chemotherapy, there was no significant difference in quality of life between the two groups (P> 0.05) The incidence of adverse reactions in patients during chemotherapy was lower than that in the control group, the difference was statistically significant (P <0.05, P <0.01). Conclusion Both FOLFOX regimen and XELOX regimen adjuvant chemotherapy in patients with stage Ⅱ / Ⅲ colon cancer can effectively improve the quality of life of patients, and the efficacy of the two chemotherapy regimens is similar, but the incidence of adverse reactions of XELOX chemotherapy regimen is low, more suitable for bone marrow reserve function Poor, poorly tolerated colon cancer patients.